Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06440707 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Transcranial Direct Current Stimulation for Treatment of Acute Ischemic Stroke

Study acronym: TESSERACT 2
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Collaborators: 4 to 5v7
  2. Start date changed from estimate of Aug 1, 2025 to Jul 15, 2025
    • Site details revised at 2 of 3 sites
    v6
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 1 to 3
    v5
  4. Study title expanded, about 3 wordsv4
  5. Lead sponsor: [Redacted] to University of California, Los Angelesv3 Show 6 more changesShow less
    • Trial status: Withheld to Not Yet Recruiting
    • Primary completion date: Jan 1, 2030
    • Study completion date: Aug 1, 2030
    • Start date: Aug 1, 2025
    • Collaborators expanded, about 13 words
    • Study title shortened, about 6 words
  6. Re-verified, no change to tracked fieldsv2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Many patients with acute ischemic stroke are ineligible for currently available standard treatments (clot-busting medication, also known as intravenous thrombolytic or mechanical removal of a clot), and many are non-responders, resulting in a low rate of excellent outcomes, which necessitates the development of novel therapies. In this study, investigators are testing a new treatment in which a weak electrical current will be applied via scalp electrodes to increase collateral blood flow to the brain and rescue the brain tissue at risk of injury. The primary aim is to find an optimal dose of this therapy that is both adequately safe and effective on imaging markers of brain tissue rescue.
Trial Details
NCT Number NCT06440707
Lead Sponsor University of California, Los Angeles
Collaborators: Johns Hopkins University, Duke University, Cedars-Sinai Medical Center, University of California, San Francisco, National Institute of Neurological Disorders and Stroke (NINDS)
Conditions
(from sponsor)		 Acute Ischemic Stroke
Related terms Ischemic Stroke
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov